PeptidePedia The community reference

Contributions of Ref_Desk_Ron

User contributions·56 logged edits·page 1 of 1

Contributions by Ref_Desk_Ron, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 26,603 edits includes activity predating the current log.

  1. 13:41, 25 Jul 2026 (diff | hist) Talk:Asymchem Laboratories 1,033 +169 /* Notability, and the oldest registry record on the wiki */ reply
  2. 18:58, 10 Jul 2026 (diff | hist) GenScript Peptides 17,833 ±0 m label the reception tally as weak, self-selected evidence at this point of use
  3. 06:42, 14 Jun 2026 (diff | hist) Methionine oxidation 5,001 ±0 add the counterion determination method by name
  4. 00:47, 9 May 2026 (diff | hist) Satiety signalling 5,593 ±0 m attribute the gastric-emptying effect to the study that measured it
  5. 10:26, 30 Apr 2026 (diff | hist) Talk:Vial 1,581 +65 /* Should the excess-volume table be here or at Underfilling? */ reply
  6. 09:02, 23 Apr 2026 (diff | hist) Guangzhou JEEP Biotechnology 15,452 ±0 expand §Notability and coverage
  7. 09:48, 20 Apr 2026 (diff | hist) Talk:Karl Fischer titration 1,233 +137 /* Should the mass-balance table give ranges or single figures? */ reply
  8. 11:30, 19 Apr 2026 (diff | hist) Talk:Cold chain 2,214 +381 /* RfC: should this article cover consumer shipping practice? */ reply
  9. 14:48, 15 Apr 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 611 +179 /* GIP-incompetence: sourcing and terminology */ reply
  10. 10:20, 9 Apr 2026 (diff | hist) Talk:Syringe dead space 1,307 +218 /* Is the community measurement tally worth citing at all? */ reply
  11. 15:10, 8 Apr 2026 (diff | hist) Talk:Incretin effect 1,022 +134 /* Measurement methods: mention the glucagon secretion measurement too? */ reply
  12. 08:15, 9 Mar 2026 (diff | hist) Talk:Glucagon-like peptide-1 959 +77 /* Readability of the signalling section */ reply
  13. 10:31, 8 Mar 2026 (diff | hist) Talk:Glucagon-like peptide-1 537 +443 /* Readability of the signalling section */ new section
  14. 10:40, 5 Mar 2026 (diff | hist) Talk:Lyophilisation 1,581 +95 /* Worked sublimation example: single vial or batch? */ reply
  15. 11:50, 28 Feb 2026 (diff | hist) Talk:Enteroendocrine L cell 885 +216 /* Plasticity section: obesity claim needs updating */ reply
  16. 11:10, 24 Feb 2026 (diff | hist) Talk:Beyond-use date 1,666 +382 /* RfC: are beyond-use date and expiration date being conflated across the wiki? */ reply
  17. 10:45, 20 Feb 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 1,096 +229 /* Requested move: → GIP */ reply
  18. 10:44, 16 Feb 2026 (diff | hist) Talk:Reconstitution calculator 1,444 +125 /* Requested move: → Peptide reconstitution calculator */ reply
  19. 10:15, 11 Feb 2026 (diff | hist) Talk:Multi-dose vial 1,729 +232 /* Does adding bacteriostatic water make a preparation preserved? */ reply
  20. 07:42, 1 Feb 2026 (diff | hist) Insulin secretion 6,940 ±0 expand §Amplifying pathways
  21. 11:37, 26 Jan 2026 (diff | hist) Talk:Glucagon-like peptide-1 1,444 +102 /* Requested move: → GLP-1 */ reply
  22. 04:38, 25 Jan 2026 (diff | hist) Crude peptide 4,775 ±0 correct the freezer temperature range given for long-term storage
  23. 17:37, 30 Dec 2025 (diff | hist) Peptide stability table 6,886 +88 correct the units on the output field
  24. 18:19, 25 Dec 2025 (diff | hist) International nonproprietary name 4,356 ±0 label the animal data as animal data in the sentence, not only in the section heading
  25. 19:06, 17 Nov 2025 (diff | hist) Hubei Jianxiang Bioscience 13,060 +1,005 add the outbound storefront link, marked nofollow and sponsored per the external-links convention
  26. 09:44, 12 Nov 2025 (diff | hist) Talk:GLP-1 receptor agonist 1,233 +109 /* Requested move: → Glucagon-like peptide-1 receptor agonist */ reply
  27. 01:48, 1 Oct 2025 (diff | hist) USP General Chapter 85 4,920 ±0 fix indentation in the source
  28. 06:33, 15 Sep 2025 (diff | hist) Regulatory status by jurisdiction 4,444 ±0 m correct the agency abbreviation at first use
  29. 09:00, 7 Aug 2025 (diff | hist) Adverse effects of GLP-1 receptor agonists 5,791 ±0 m clarify that dose-dependence is reported for some effects and not others
  30. 10:02, 25 Jul 2025 (diff | hist) Talk:Cold chain 1,307 +60 /* Logger accuracy: is ±0.5 °C a standard or an expectation? */ reply
  31. 12:06, 19 Jul 2025 (diff | hist) ChinaPeptides 11,979 +1,983 add the incorporation year, attributed to the registry record
  32. 17:24, 12 Jul 2025 (diff | hist) SinoPep 4,757 +1,033 add the note that this wiki publishes no score and no league table
  33. 03:33, 18 Jun 2025 (diff | hist) SinoPep 2,939 +998 state the city and province of the registered address
  34. 12:56, 9 Jun 2025 (diff | hist) Xi'an Mokemei Biotechnology 6,325 +538 m correct the other-designations row — those are trading variants, not subsidiaries
  35. 10:21, 18 May 2025 (diff | hist) Talk:Beyond-use date 1,307 +87 /* Category 2 table: which revision, and should earlier revisions be shown? */ reply
  36. 05:50, 9 May 2025 (diff | hist) Trial data comparison 4,355 ±0 state the rounding rule the readout uses
  37. 10:34, 4 May 2025 (diff | hist) Sarcopenia 3,713 +273 m clarify that the marker is method-dependent and not comparable across platforms
  38. 11:22, 30 Apr 2025 (diff | hist) Talk:ChinaPeptides 1,244 +65 /* Which name should the article title use? */ reply
  39. 15:17, 26 Apr 2025 (diff | hist) Oral semaglutide 3,542 ±0 move the trade-name history out of the lead and into §Regulatory history
  40. 12:36, 27 Mar 2025 (diff | hist) Number needed to treat 3,631 ±0 convert the endpoint list to a table for comparability
  41. 20:07, 14 Mar 2025 (diff | hist) Grey market 2,576 ±0 m expand §What the term does not mean
  42. 09:33, 18 Feb 2025 (diff | hist) Talk:Lyophilisation 1,455 +193 /* Requested move: → Lyophilization */ reply
  43. 00:47, 10 Feb 2025 (diff | hist) Trial data comparison 2,396 +176 m add the caveat that concentration and dose are not the same quantity
  44. 02:23, 27 Jan 2025 (diff | hist) Methionine oxidation 2,680 ±0 expand §Chemistry and promoters
  45. 16:04, 19 Dec 2024 (diff | hist) Reconstitution of lyophilised peptides 3,702 +26 m convert the conversion list to a table so the three syringe scales align
  46. 20:54, 25 Nov 2024 (diff | hist) Gastric emptying 3,836 +44 m convert the receptor-distribution list to a table
  47. 20:24, 20 Nov 2024 (diff | hist) Underfilling 1,727 +619 clarify that a QR code on a certificate proves issuance, not content
  48. 11:53, 15 Oct 2024 (diff | hist) Peptide supply chain 1,378 ±0 m rm a duplicated category
  49. 11:44, 15 Oct 2024 (diff | hist) Talk:Nantong Guangyuan Chemical 1,244 +77 /* Multiple trading names: which is the title? */ reply
  50. 23:48, 6 Oct 2024 (diff | hist) Bachem Holding (Suzhou) 1,692 ±0 m sentence case in headings per PP:MOS
  51. 08:07, 3 Oct 2024 (diff | hist) Talk:Reconstitution calculator 822 +271 /* Does this page cross the line into instruction? */ reply
  52. 09:41, 2 Oct 2024 (diff | hist) Talk:Reconstitution calculator 400 +504 /* Does this page cross the line into instruction? */ new section
  53. 06:58, 2 Oct 2024 (diff | hist) Custom peptide synthesis 2,139 +2,139 N new article: supply and handling, expansion welcome
  54. 00:07, 23 Sep 2024 (diff | hist) Oral semaglutide 2,129 ±0 m add the discontinued indication with its date
  55. 09:41, 14 Aug 2024 (diff | hist) Incretin effect 3,698 ±0 add the species in which the knockout work was done
  56. 09:00, 28 Jun 2024 (diff | hist) Wuhan Wansheng Biotechnology 1,764 +1,764 N create organisation article per PP:VN